UPDATE: Wedbush Securities Upgrades Alere to Outperform

Wedbush Securities has published a research report on Alere ALR upgrading the stock from Neutral to Outperform after the company's latest 8-K showed FDA progress. In the report, Wedbush writes, "Shares of ALR are off 18% on the last two weeks versus a 3% decline in both the S&P 500 and BTK index. ALR remains a very complicated story, but the bar appears low for positive FDA developments, flu activity, DM stabilization, and other catalysts. Our $23 price target still assumes zero DM value and a 2.3x EV/sales multiple on the professional dx and 2x EV/sales multiple on toxicology sales. Our price target also assumes a 2012E P/E multiple of ~10x and FCF yield of ~4.7%. ALR trades at a discount to the group on a 2012E P/E multiple basis (8x vs. 18x) and EV/sales basis (1.4x vs. 3.4x), while ALR is on track to post a 2012E levered FCF yield of ~5.2%, a discount to the peer group median of ~4.6%." Wedbush Securities maintains its $23 price target on Alere, which is currently trading up $0.18 from yesterday's $18.32 closing price.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesAnalyst RatingsWedbush Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!